As expected, Csn-B treatment increased the expression of NR4A1 at the transcriptional and protein levels (Fig. 7a and Supplementary Fig. 8a, b), followed by the inhibited growth of BC cells in a dose-dependent manner (Fig. 7b). Here, NR4A1 is linked to breast cancer.